Our Recommendations
- Ulcère de Buruli : prise en charge de l' infection à Mycobacterium ulcerans (2001)
- Traitement de l’infection à mycobacterium ulcerans (ulcère de Buruli) (2012)
- Ulcère de buruli : diagnostic de l' infection à mycobacterium ulcerans (2001)
- Laboratory diagnosis of Buruli ulcer (2014)
- Diagnostic de l’ulcère de Buruli au laboratoire (2014)
New Publications
- Rapid Extraction Method of Mycobacterium ulcerans DNA from Clinical Samples of Suspected Buruli Ulcer Patients (2019)
- A combined effort of 11 laboratories in the WHO African region to improve quality of Buruli ulcer PCR diagnosis: The “BU-LABNET” (2024)
- Ulcère de Buruli : prise en charge de l' infection à Mycobacterium ulcerans (2001)
- Traitement de l’infection à mycobacterium ulcerans (ulcère de Buruli) (2012)
- Treating Buruli Ulcer (2013)
Filter
35
Featured
Recommendations
11
Language
Document type
Studies & Reports
16
Guidelines
10
Manuals
6
Training Material
1
App
1
Resource Platforms
1
Countries / Regions
Ghana
1
Nigeria
1
Global
1
Authors & Publishers
Publication Years
Category
Clinical Guidelines
12
Pharmacy & Technologies
4
Countries
2
Toolboxes
Data available for your search include drug targets, tested compounds, existing drugs, ethnopharmacological plants, and information on the genome of M. ulcerans
Skin NTDs App
recommended
Recognizing neglected tropical diseseases through changes on the skin.
App for Android and IOS, free of charge. The App is available in English and French, with plans to explore translations into other languages, such as Portuguese and Spanish, to better serve diverse communities.
A patient's skin...
Pharmaceuticals 2024, 17(6), 691; https://doi.org/10.3390/ph17060691
PLoS Negl Trop Dis 16(11): e0010908. https://doi.org/10.1371/journal.pntd.0010908
In 2009, WHO’s Second International Conference on Buruli Ulcer Control and Research resolved to strengthen the capacity of national laboratories to confirm cases of the disease, but advised that “efforts are still needed to develop simple diagnostic tools usable in the field as well as disabilit...
This manual details a collaboratively developed intervention to detect and refer Buruli ulcer, Hydrocele, Leprosy
and Lymphedema cases through the use of integrated approaches at community levels. This intervention has
been developed as part of the consortium in partnership with the Nigerian Feder...
L’ulcère de Buruli, une infection causée par Mycobacterium ulcerans, touche plus de 33 pays dans le monde, mais un peu moins de la moitié seulement de ces pays communiquent régulièrement des données sur la maladie à l’OMS.
Phillips and colleagues have shown that rifampicin combined with clarithromycin is non-inferior to RS8, and is safer. This much anticipated trial provides us with a high degree of confidence that an 8-week course of oral rifampicin and clarithromycin should now be the cornerstone of the treatment of...
The Lancet olume 395, ISSUE 10232, P1259-1267, April 18, 2020. Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulcerans infection that damages the skin and subcutis. It is most prevalent in western and central Africa and Australia. Standard antimicrobial treatment with oral rifa...
Au total, 18 laboratoires de 13 pays ont participé aux quatre cycles d'AQE : 10 laboratoires de huit pays africains endémiques, dont quatre ont participé aux quatre cycles et trois à trois cycles. Les résultats globaux ont montré que la performance médiane de ces laboratoires s'est amélioré...
Research to develop point-of-care tests is in progress. Treatment of Buruli ulcer comprises 8 weeks of combined antibiotics (rifampicin and clarithromycin). Complementary therapies such as wound care, skin graft and prevention of disability are needed in some cases to ensure full recovery.
The targ...
A total of 18 laboratories from 13 countries participated in the four rounds of EQA: 10 laboratories from eight African endemic countries, four of which participated in all four rounds and three in three rounds. The overall results showed that the median performance of these laboratories improved ov...
Diagnostics 2019, 9(4), 204; https://doi.org/10.3390/diagnostics9040204
The skin of a patient is the first and most visible structure of the body that any health-care worker encounters during the course of an examination. To the patient, it is also highly visible, and any disease that affects it is noticeable and will have an impact on personal and social well-being. Th...
The meeting was held from 26 to 27 March 2018 to review and discuss the following topics:
Advances and challenges in the use of fTLC, and new approaches to detecting mycolactone using monoclonal antibodies (mAbs).
The status of development of rapid diagnostic tests (RDTs) targeting the MUL...
Nat Commun 9, 5370 (2018). https://doi.org/10.1038/s41467-018-07804-8. Mycobacterium ulcerans is the causative agent of Buruli ulcer, a neglected tropical skin disease that is most commonly found in children from West and Central Africa. Despite the severity of the infection, therapeutic options are...
Volume 2016 | Article ID 5310718 | https://doi.org/10.1155/2016/5310718. Buruli ulcer (BU) is a necrotizing cutaneous infection caused by Mycobacterium ulcerans. Early diagnosis is crucial to prevent morbid effects and misuse of drugs. We review developments in laboratory diagnosis of BU, discuss li...
Laboratory diagnosis of Buruli ulcer
recommended
A manual for health care providers.
This manual provides expert guidance on the laboratory techniques and procedures used in the diagnosis of Buruli ulcer, a disease caused by Mycobacterium ulcerans. Aimed at laboratory technicians and scientists working on this disease, the manual details the exac...
Diagnostic de l’ulcère de Buruli au laboratoire
recommended
Manuel destiné au personnel de santé. Le présent manuel est un guide spécialisé sur les techniques et les méthodes de laboratoire à utiliser pour le diagnostic de l’ulcère de Buruli, une maladie provoquée par Mycobacterium ulcerans. Destiné aux techniciens et aux scientifi ques de labora...
A review of prospects for existing antibiotics ad new therapeutics
